This page uses content from Wikipedia and is licensed under CC BY-SA.

Arformoterol

Arformoterol
Arformoterol.svg
Arformoterol ball-and-stick model.png
Clinical data
Trade namesBrovana
AHFS/Drugs.comMonograph
MedlinePlusa602023
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Inhalation solution for nebuliser
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
Protein binding52–65%
Elimination half-life26 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H24N2O4
Molar mass344.405 g/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]

It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

  1. ^ "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.

External links